Skip to main content
Equibles
AGEN $6.73 -2.04%
AGEN logo
AGEN · Agenus Inc
Track AGEN — free

Use AGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.73 -0.14 (-2.04%) At close · Nov 13 Q2 2025 earnings call transcript
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Nov 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the filing date of this Quarterly Report on Form 10-Q.”
View the 10-Q filed Nov 5, 2026
Market Cap
$304.51M
Shares
45.25M
Volume · Nov 13 465.28K Avg daily vol (3M) 962.63K
All webcasts

Earnings call · FY2026 Q3

Agenus Inc (AGEN) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $31.49M +4.1% YoY
Diluted EPS $0.02 -99% YoY
Gross margin · derived Q4 100.0% +2.1 pp YoY
Net income $2.73M -95.7% YoY
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 5, 2026
Agenus Inc. reported third-quarter revenue of $31.5 million and operating income of $11.4 million. Armenia granted the first worldwide marketing authorizations for Botvymo® and Evamplix®, while ROBBIN is targeted to enroll its first patient in Q1 2027.
10-Q report · filed Nov 5, 2026
Agenus plans ROBBIN, a global Phase 3 trial of neoadjuvant BOT/BAL in Stage II and Stage III MSS colon cancer. Substantial doubt exists about going concern; existing resources are expected to fund operations through the third quarter of 2027.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Nov 5, 2026 10-Q report Filed Nov 5, 2026
Full-screen source Call document

AGEN alerts

Agenus Inc

Create a free account or sign in to receive transcript alerts at your email address.

Continue to sign in
Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →

Embed Agenus Inc earnings calls on your site

Pick a widget, match your page, then paste the code where it should appear.

Widget
Theme
Accent color Pro

Match your site's colors with Pro. The Equibles credit stays on every plan.

Embed code 

                    
The widget credits Equibles and keeps the link below it on every plan.

                

            


            

                Preview